All In Biotech

Drug Trial Radar · NCT04435990

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Clinical Trial With SCIT in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to Dpt. and/or D. Farinae

Last checked: Nov 20, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 6, 2020

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Inmunotek S.L.Industry
Sponsor type
Industry
Collaborators
BioClever 2005 S.L.
First posted
Jun 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.

Conditions

  • Rhinitis, Allergic
  • Rhinoconjunctivitis
  • Asthma, Allergic

Interventions

  • 10,000 MM09Biological

    Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL

  • 30,000 MM09Biological

    Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL

  • Placebo subcutaneousBiological

    The same solution and presentation as the active treatment, but without active ingredients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CSMS: Combined Symptoms and Medication ScoreTime frame: 12 months

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain · Recruiting

  • Hospital Universitario San Juan de Alicante

    Alicante, Spain · Recruiting

  • Clínica Dermatológica y Alergia

    Badajoz, Spain · Recruiting

  • Hospital Quironsalud Clideba

    Badajoz, Spain · Recruiting

  • Hospital Sant Pere Claver

    Barcelona, Spain · Recruiting

  • Clínica Corachan

    Barcelona, Spain · Recruiting

  • Hospital Universitari Dexeus

    Barcelona, Spain · Recruiting

  • Cenvi Medic

    Barcelona, Spain · Recruiting

  • Allergocenter

    Barcelona, Spain · Active not recruiting

  • Clinica privada

    Bilbao, Spain · Withdrawn

  • Centro Médico ASISA Dr. Lobatón

    Cadiz, Spain · Recruiting

  • Centro Médico Puerto

    Cadiz, Spain · Recruiting

  • Hospital Quiron Salud Córdoba

    Córdoba, Spain · Recruiting

  • Hospital Polusa

    Lugo, Spain · Recruiting

  • Clinica privada

    Málaga, Spain · Recruiting

  • Hospital Comarcal de Melilla

    Melilla, Spain · Recruiting

  • Clinica Privada

    Murcia, Spain · Not yet recruiting

  • Alergocantabria

    Santander, Spain · Recruiting

  • Hospital Quiron Infanta Luisa

    Seville, Spain · Recruiting

  • Clinica Lanuza

    Valencia, Spain · Recruiting

  • Hospital Universitario Y Politecnico La Fe

    Valencia, Spain · Recruiting

  • Clinica IMED

    Valencia, Spain · Withdrawn

  • Hospital de Sagunto

    Valencia, Spain · Withdrawn

  • Hospital Provincial de Conxo

    Santiago de Compostela, A Coruña, Spain · Recruiting

  • IMED Elche

    Elche, Alicante, Spain · Recruiting

  • Hospital Universitario de Torrevieja

    Torrevieja, Alicante, Spain · Recruiting

  • Clinica Tecma

    Valencia, Alzira, Spain · Completed

  • Clinica Virgen del Rosario

    Algeciras, Cadiz, Spain · Active not recruiting

  • Hospital HLA Jerez Puerta Sur

    Jerez de la Frontera, Cádiz, Spain · Withdrawn

  • Hospital Dr. Peset

    Valencia, España, Spain · Recruiting

  • Hospital General Universitario Santa Maria de Rosell

    Cartagena, Murcia, Spain · Withdrawn

  • Hospital Rivera Povisa

    Vigo, Pontevedra, Spain · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.